M. Cutler

发表

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

P. Dormitzer, John L. Perez, D. Cooper, 2020, medRxiv.

Neutralizing Activity of BNT162b2-Elicited Serum

P. Dormitzer, K. Swanson, D. Cooper, 2021, The New England journal of medicine.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

W. Gruber, D. Scott, P. Supe, 2017, Human vaccines & immunotherapeutics.

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age

John L. Perez, Ping Li, E. Aris, 2020, Human vaccines & immunotherapeutics.

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan

A. Gurtman, W. Gruber, D. Scott, 2015, The Pediatric infectious disease journal.

Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine

John L. Perez, Ping Li, B. Quiambao, 2020, Human vaccines & immunotherapeutics.

Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses.

D. Cooper, J. Eldridge, F. Nasar, 2004, Vaccine.

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

P. Dormitzer, K. Swanson, D. Cooper, 2022, NPJ vaccines.

Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6–17 Years of Age in India: An Open-label Trial

W. Gruber, D. Scott, C. Juergens, 2017, The Pediatric infectious disease journal.

Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report.

P. Dormitzer, K. Swanson, D. Cooper, 2021, The New England journal of medicine.

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

P. Dormitzer, John L. Perez, K. Swanson, 2020, Nature.

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

P. Dormitzer, John L. Perez, D. Cooper, 2021, Nature.

Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine

R. Sellers, C. Rohde, C. Bowman, 2021, Reproductive Toxicology.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

Vineet D. Menachery, P. Dormitzer, K. Swanson, 2021, bioRxiv.

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Vineet D. Menachery, P. Dormitzer, K. Swanson, 2021, bioRxiv.

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

P. Dormitzer, K. Swanson, D. Cooper, 2021, Nature.

Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine

P. Dormitzer, John L. Perez, K. Swanson, 2020, medRxiv.

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection

K. Swanson, D. Cooper, U. Şahin, 2022, bioRxiv.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Vineet D. Menachery, P. Dormitzer, K. Swanson, 2021, Nature Medicine.

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

K. Swanson, D. Cooper, K. Jansen, 2022, Cell Host & Microbe.

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine

K. Swanson, D. Cooper, K. Jansen, 2022, Nature Communications.

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine

N. Kitchin, K. Swanson, D. Cooper, 2022, bioRxiv.

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants

P. Dormitzer, K. Swanson, D. Cooper, 2022, npj Vaccines.

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

P. Dormitzer, K. Swanson, D. Cooper, 2021, NPJ vaccines.

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

John L. Perez, Ping Li, E. Aris, 2020, BMC Infectious Diseases.

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

P. Dormitzer, K. Swanson, D. Cooper, 2021, Research square.

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

N. Kitchin, K. Swanson, D. Cooper, 2023, The New England journal of medicine.

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

P. Dormitzer, K. Swanson, D. Cooper, 2021, The New England journal of medicine.

Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

P. Dormitzer, John L. Perez, K. Swanson, 2021, Nature.

BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants

P. Dormitzer, K. Swanson, D. Cooper, 2021, bioRxiv.

Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine

K. Swanson, D. Cooper, K. Jansen, 2022, bioRxiv.

A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.

John L. Perez, P. Peyrani, C. Cutland, 2023, Vaccine.

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Older Adults.

A. Gurtman, K. Swanson, W. Gruber, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

N. Kitchin, K. Swanson, K. Koury, 2024, Vaccines.